"Despite taking billions of taxpayer dollars for drug development, these Big Pharma companies unleashed an army of patent attorneys to keep life-saving medicine exclusive and more expensive for seniors and other patients," Tony Carrk stated, highlighting the paradox of public funding versus high drug prices. This sheds light on how law firms act as barriers keeping essential medications out of reach for those who need them most.
Carrk emphasized that when the initial negotiation list was announced, companies rushed to ensure their life-saving medications remain 'expensive and exclusive,' indicating that these corporations would go to great lengths to maintain their profits even at the expense of public health.
The report exposed that companies bent patent law to maintain a monopoly on certain drugs and prevent market competition. This underscores the serious implications of patent manipulation in the pharmaceutical industry, especially concerning access and affordability for patients.
Johnson & Johnson's use of 'pay-to-delay' agreements regarding the blood thinner Xarelto, where they paid competitors to prevent the release of lower-cost generics, serves as a stark example of how companies maneuver within the legal system to suppress market competition and sustain high drug prices.
[
Collection
]
[
|
...
]